Antiagregación plaquetaria: stents, isquemia y sangrado ¿Qué sabemos al respecto? / Platelet antiaggregation: stents, ischemia and bleeding What do we know about it?
Rev. méd. Maule
; 37(1): 105-113, jun. 2022. tab, ilus
Article
de Es
| LILACS
| ID: biblio-1397776
Bibliothèque responsable:
CL1.1
ABSTRACT
Antiplatelet therapy and percutaneous coronary intervention are two of the most important interventions in the management of coronary artery disease. In the last 20 years there has been groundbreaking advances in the pharmacotherapy and stent technology. Bleeding is the most feared complication of antiplatelet therapy, mainly due to the increase in major adverse cardiovascular events besides the bleeding itself. Different clinical decision tools have developed with the aim to define which patients have a high ischemic or bleeding risk, thus individualizing treatment.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
LILACS
Sujet principal:
Antiagrégants plaquettaires
/
Association de médicaments
/
Intervention coronarienne percutanée
Type d'étude:
Prognostic_studies
Limites:
Humans
Langue:
Es
Journal:
Rev. méd. Maule
Sujet du journal:
MEDICINA
Année:
2022
Type de document:
Article
Pays d'affiliation:
Chili